Capreit (TSE:CAR – Free Report) – Research analysts at Ventum Cap Mkts issued their Q3 2024 earnings estimates for shares of Capreit in a report released on Monday, November 4th. Ventum Cap Mkts analyst D. Chrystal forecasts that the company will post earnings per share of $0.67 for the quarter. Ventum Cap Mkts currently has a “Hold” rating on the stock.
Capreit (TSE:CAR – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported C$0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$0.64 by C$0.02. The company had revenue of C$278.13 million during the quarter.
Capreit Price Performance
Capreit Dividend Announcement
The company also recently declared a monthly dividend, which will be paid on Friday, November 15th. Investors of record on Thursday, October 31st will be paid a dividend of $0.125 per share. This represents a $1.50 annualized dividend and a yield of ∞. The ex-dividend date of this dividend is Thursday, October 31st.
About Capreit
Avis Budget Group, Inc, together with its subsidiaries, provides car and truck rentals, car sharing, and ancillary products and services to businesses and consumers. It operates the Avis brand, that offers vehicle rental and other mobility solutions to the premium commercial and leisure segments of the travel industry; the Budget Truck brand, a local, and one-way truck and cargo van rental businesses with a fleet of approximately 20,000 vehicles, which are rented through a network of approximately 465 dealer-operated and 385 company-operated locations that serve the consumer and light commercial sectors in the continental United States; and the Zipcar brand, a car sharing network.
Featured Stories
- Five stocks we like better than Capreit
- Options Trading – Understanding Strike Price
- Intel: Is Now the Time to Be Brave?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Capreit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capreit and related companies with MarketBeat.com's FREE daily email newsletter.